Needham & Company analyst, Serge Belanger, reiterated his Buy rating on Aerie Pharma (NASDAQ: AERI) ahead of two major catalysts ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE